
|Articles|September 15, 2002
Glaucoma patients experience hyperemia with medications
Two glaucoma drugs approved last year, travoprost (Travatan, Alcon) and bimatoprost (Lumigan, Allergan), are associated with higher rates of hyperemia than the more established drug latanoprost (Xalatan, Pharmacia). However, the hyperemia is seldom a clinically significant side effect, according to a sampling of physicians who are familiar with all three drugs.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
UPDATE: STAAR postpones Alcon merger vote, Broadwood calls for removal of board members
2
VR and imaging advancements showcased at AAO 2025
3
ONL Therapeutics randomizes first patient in phase 2 GALAXY trial evaluating xelafaslatide
4
Advancements in femtosecond laser technology benefit surgeons and patients
5

















































.png)


